JAK inhibitors have good efficacy in patients with some type I interferonopathies, including STING-associated vasculopathy, infantile-onset (SAVI), and proteasome-associated autoinflammatory syndrome (PRAAS) [13–16]. The gene discussed is STING1; the disease is STING-associated vasculopathy with onset in infancy.